Global law firm Dentons advised Farmak, Ukraine’s leading pharmaceutical company, on a series of strategic acquisitions from a portfolio company of private equity house Novator. Farmak acquired pharmaceutical marketing companies in the Czech Republic and Slovakia, together with the relevant IP rights and trademarks, and in a separate transaction, a Ukrainian business owning a product portfolio, selected assets, and IP rights and trademarks.

Farmak has a 6% share of the Ukrainian pharmaceutical market and exports its products to more than 50 countries. Through this transaction, Farmak will increase its presence in the European Union while strengthening its position in the cardiology and cough and cold segments.

Counsel Lukáš Výmola (Prague) and partners Adam Mycyk (Kyiv) and Petr Zákoucký (Prague) led Dentons’ cross-practice and cross-jurisdictional team. The team included associates Petr Müller, Adam Přerovský, Štěpánka Havlíková, Blanka Crháková, Jan Tylš, Tomáš Jonáš and Michael Mráček in Prague; partner Juraj Gyárfáš and associates Ján Dulovič, Alen Gondek, Gabriel Kulik, Michal Distler and Tatiana Jevčáková in Bratislava; partner Maksym Sysoiev, counsel Anna V. Tkachenko, Oksana Horban and Evgenia Prudko, and associates Volodymyr Omelchenko, Victor Marchan and Roman Mehedynyuk in Kyiv, partner Rob Irving in Budapest, and counsel Clemence Personne in Luxembourg.

Commenting on the transaction, Adam Mycyk said: “We are very proud to have supported our client´s strategy to evolve into an international company, drawing on our cross-border M&A, pharmaceutical industry, and IP expertise.”

Dmytro Shapkin, Chief Transformation Officer at Farmak said: “We appreciated Dentons’ guidance in successfully closing this deal. We were impressed with the high quality of their legal advice, outstanding commitment, as well as smooth cross-border cooperation.”

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com